Greenup Street Wealth Management LLC Acquires 1,115 Shares of Eli Lilly and Company $LLY

Greenup Street Wealth Management LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 37.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,131 shares of the company’s stock after acquiring an additional 1,115 shares during the quarter. Eli Lilly and Company makes up about 0.6% of Greenup Street Wealth Management LLC’s holdings, making the stock its 29th biggest position. Greenup Street Wealth Management LLC’s holdings in Eli Lilly and Company were worth $4,780,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Marshall & Sterling Wealth Advisors Inc. boosted its stake in shares of Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after buying an additional 15 shares during the period. AlphaCentric Advisors LLC purchased a new position in Eli Lilly and Company in the first quarter worth $42,000. Foresight Capital Management Advisors Inc. purchased a new position in shares of Eli Lilly and Company in the 3rd quarter valued at about $49,000. Caitlin John LLC purchased a new position in Eli Lilly and Company in the second quarter valued at about $64,000. Finally, IMG Wealth Management Inc. lifted its position in shares of Eli Lilly and Company by 500.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock valued at $72,000 after acquiring an additional 50 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,415.64 on Monday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The stock has a fifty day moving average of $1,197.72 and a two-hundred day moving average of $1,092.57. The company has a market capitalization of $1.33 trillion, a price-to-earnings ratio of 45.95, a PEG ratio of 1.80 and a beta of 0.40. Eli Lilly and Company has a fifty-two week low of $834.19 and a fifty-two week high of $1,449.68.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same period in the prior year, the firm earned $7.02 EPS. The firm’s quarterly revenue was up 38.6% on a year-over-year basis. On average, analysts anticipate that Eli Lilly and Company will post 35.18 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is 22.46%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Analyst Upgrades and Downgrades

LLY has been the topic of several research analyst reports. Leerink Partners boosted their price target on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 21st. Truist Financial restated a “buy” rating and issued a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday. Argus raised their price objective on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research note on Friday. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,413.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, October 20th. Finally, JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,398.43.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.